A
Actuate Therapeutics, Inc. (ACTU)
NGM – Real vaqt narxi. Valyuta: USD
2.89
-0.08 (-2.86%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
2.89
-0.08 (-2.86%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Actuate Therapeutics, Inc., klinik davrlardagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda saratonni davolash uchun terapiyalarni ishlab chiqadi. Kompaniyaning asosiy mahsulot nomzodi elraglusib in'ektsiyasi bo'lib, u glikogen sintaza kinaza-3 ingibitori bo'lib, metastatik oshqozon osti bezi o'simtasini davolash uchun 2-bosqich sinovida. Kompaniya, shuningdek, Ewing sarkomasi, neyroblastom va bolalar leykemiyasi kabi refrakter pediatrik malignansiyalarni davolash uchun 1/2-bosqich sinovida bo'lgan elraglusibni ishlab chiqadi. Kompaniya ilgari Apotheca Therapeutics, Inc. nomi bilan tanilgan va 2015 yil oktyabr oyida Actuate Therapeutics, Inc. nomini o'zgartirgan. Actuate Therapeutics, Inc. 2015 yilda ro'yxatga olingan va Fort Worth, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Alan Kozikowski Ph.D. | Scientific Founder and Advisor |
| Dr. Andrew P. Mazar Ph.D. | Co-Founder & COO |
| Mr. Daniel M. Schmitt | CEO, President & Director |
| Mr. Paul J. Lytle CPA | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | DEFA14A | actuate_defa14a.htm |
| 2026-04-09 | ARS | actuate_ars.pdf |
| 2026-04-06 | DEFA14A | actu_defa14a.htm |
| 2026-04-06 | DEF 14A | actuate_def14a1.htm |
| 2026-03-26 | 10-K | actuate_i10k-123125.htm |
| 2026-01-12 | 8-K | actuate_8k.htm |
| 2025-11-28 | 8-K | actuate_8k.htm |
| 2025-11-21 | 8-K | actuate_8k.htm |
| 2025-11-13 | 10-Q | actuate_i10q-093025.htm |
| 2025-09-10 | 8-K | actuate_8k.htm |